An interventional study of Pterostilbene-silybin-nicotinamide riboside and Control Group in Oxidative Stress, Physical Activity and Antioxidant Effect, sponsored by Fundació Eurecat. Recruiting at 1 site in Spain. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-27.
Sponsored by Fundació Eurecat · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 597 studies in Motor Activity with a site in Spain — 148 open to participants now, 184 under way, 1 of them phase 3. Motor Activity · Spain.
Among the 597 studies in Motor Activity with a site in Spain, this one is the 514th largest by planned enrollment of the 539 interventional ones that give a count, is one of 77 that started in 2025, is one of 515 with no phase, reaches primary completion later than 57 of the 183 other live ones, and was the 485th registered.
9,827 studies on the registry are indexed under Motor Activity; 1,911 are open to participants now.
Browse Motor Activity studies →148 of the 597 studies in Motor Activity with a site in Spain are open now. Recruiting first, the newest first:
Universidad Pública de Navarra · Sites in Spain
Ages 65+
University of Valencia · Sites in Spain
Ages 60–99
Universidad San Jorge · Sites in Spain
Ages 18–65 · Healthy volunteers
Institut Investigacio Sanitaria Pere Virgili · Sites in Spain
Ages 18+ · Women only
Alberto Bermejo Franco · Sites in Spain
Ages 70+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 1,207 Motor Activity studies recruiting now, 524 (43%) set no upper age limit and 538 (45%) stop at 75 or younger; 180 take children under 18; 420 take healthy volunteers.
This study: 18 Years to 50 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
597 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 9 · Phase 4 4
First in 2004; this study’s year is marked. 77 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 14 is below the median of 60 across 8,412 interventional studies indexed under Motor Activity.
Median enrollment 80 across the 539 interventional studies, 145 across the 58 observational. Of the 335 that completed or were terminated, 5 (1%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 597 have an industry lead sponsor. The 10 most frequent:
Fundació Eurecat is the lead sponsor of 21 studies on the registry; 5 are open to participants now.
Fundació Eurecat has 2 studies filed under Motor Activity — fewer than ten, so there is no comparison to draw.
47 of the studies in Motor Activity with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07183241Universidad Pública de NavarraHospital-to-Home Rehabilitation Through Exercise and Cognitive Training | 2026-12 |
| NCT07489391University of DeustoConcomitant Use of Radiotherapy and Integrated Exercise - Lung Cancer | 2026-12 |
| NCT07232511University of ValenciaExercise-induced Hypoalgesia Effects of Blood Flow Restriction in People With Rotator Cuff-related Shoulder Pain | 2026-12 |
| NCT06446596University of ValenciaTelerehabilitation-based Exercises vs Standard Home-based Exercise in Low Back Pain | 2026-12 |
| NCT06948500Cardenal Herrera UniversityEffectiveness of an IVR-based Therapeutic Exercise Program With Altered Visual Feedback in Fibromyalgia Patients | 2026-12-01 |
Add all 47 to your calendar (.ics) → With an account.
Among the 597 studies in Motor Activity with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the effects of the dietary supplement ccPT-SIL-NR, which contains pterostilbene (ccPT), silybin (SIL), and nicotinamide riboside (NR), on oxidative stress markers after a high-intensity exercise session. The primary objective is to assess changes in blood malondialdehyde (MDA) levels.
Secondary objectives include evaluating the effects on oxidative DNA damage (8-OHdG), lipid peroxidation (F2-isoprostanes), total antioxidant capacity (FRAP assay), glutathione ratio (GSH/GSSG), antioxidant enzyme activity (SOD, CAT, GPx), inflammatory markers (hsCRP, MCP-1, IL-6), muscle damage markers (LDH, CK), cortisol levels, renal function (creatinine), and gene expression patterns through transcriptomic analysis.
The study will include 14 healthy male participants in a randomized, tripple-blind, placebo-controlled, crossover design. Each participant will receive both the ccPT-SIL-NR supplement and placebo for 14 days each, separated by a washout period of at least one week. A high-intensity exercise test will be performed at the end of each supplementation period. Total study duration per participant will be a minimum of 6 weeks.
This study aims to evaluate the effect of a nutritional supplement combining pterostilbene, silybin, and nicotinamide riboside on oxidative stress induced by high-intensity exercise. Oxidative stress occurs when there is an imbalance between the production of reactive oxygen species and the body's ability to counteract their harmful effects. High-intensity physical activity is known to increase oxidative stress, potentially leading to cellular damage and inflammation. The supplement under investigation has shown antioxidant properties in preclinical models, and this trial seeks to explore its efficacy in humans. The trial is a randomized, triple-blind, placebo-controlled, and crossover study. Fourteen healthy, physically active men aged 18-50 will be recruited. Each participant will take either the supplement or placebo twice daily for 14 days, followed by a treadmill exercise session at 80% of their VO₂ max. After a washout period, participants will switch treatments and repeat the protocol. Blood and urine samples will be collected both at baseline (prior to supplement intake and without any physical activity) and after the exercise test to evaluate markers of oxidative stress, inflammation, muscle damage, and antioxidant capacity. The main outcome is the change in plasma levels of malondialdehyde (MDA). Secondary outcomes include urinary 8-OHdG and F2-isoprostanes, antioxidant enzyme activities, cortisol levels, and gene expression profiles. This study will help to determine whether the supplement can mitigate exercise-induced oxidative stress and support recovery in recreational athletes.
Participants will attend seven in-person visits:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Able to read, write, and speak either Catalan or Spanish.
MET value for vigorous activity = 8 × minutes × days per week.
Exclusion Criteria:
Alcohol consumption of 4 or more Standard Drink Units (SDUs) per day or 28 SDUs per week.*
*One SDU is defined as 10 grams of alcohol. This corresponds approximately to: 1 glass of wine (120 mL), 1 beer (330 mL), or 1 small spirit (25 mL); 2 SDUs correspond to 1 glass of brandy or liqueur (55 mL), 1 whiskey (70 mL), or a mixed drink (75 mL).
Presence of chronic gastrointestinal diseases* or cancer.**
*Chronic gastrointestinal diseases include those in an active phase that may interfere with nutrient absorption. Common examples include gastritis, hiatal hernia, Crohn's disease, celiac disease, irritable bowel syndrome, diverticulitis, diverticulosis, chronic constipation, and ulcerative colitis.
**Individuals with a history of cancer may be included only if they are in complete remission at the start of the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants treated with Microcrystalline Cellulose for 14 days
Dietary Supplement: Control Group
Participants treated with pterostilbene, silybin, and nicotinamide riboside for 14 days
Dietary Supplement: Pterostilbene-silybin-nicotinamide riboside
Participants will take 2 sachets, each containing 340 mg of ccPT, silybin and nicotinamide riboside, and 1.91 g of excipients.
Participants will take 2 sachets, each containing 340 mg microcrystalline cellulose, and 1.91 g of excipients.
Malondialdehyde (MDA) plasma levels
Plasma MDA levels will be measured using commercial ELISA kits
Time frame: At week 1, week 3, week 4 and week 6.
Age
The age of the volunteers will be recorded in the case report form.
Time frame: At week 0 (pre-selection visit)
Height (cm)
Height measured with standardized method
Time frame: At week 0 (pre-selection visit)
Body Weight (Kg)
Weight measured using the InBody 970 device
Time frame: At week 0 (pre-selection visit)
Body Mass Index (BMI) (Kg/m^2)
Weight and height will be combined to report BMI in kg/m\^2
Time frame: At week0 (pre-selection visit)
Urine 8-hydroxy-2'-deoxyguanosine (8-OHdG) levels
Urine 8-OHdG levels will be measured using commercial ELISA kits
Time frame: At week 1, week 3, week 4 and week 6.
Urine F2-isoprostanes levels
Urine F2-isoprostanes levels will be measured using commercial ELISA kits
Time frame: At week 1, week 3, week 4 and week 6.
Plasma antioxidant capacity
Plasma antioxidant capacity will be measured by the Ferric Reducing Antioxidant Power assay using ELISA kits.
Time frame: At week 1, week 3, week 4 and week 6.
Erythrocyte Redox Status (GSH/GSSG Ratio)
The ratio of reduced glutathione (GSH) to oxidized glutathione (GSSG) will be measured in erythrocytes using commercial ELISA kits.
Time frame: At week 1, week 3, week 4 and week 6.
Superoxide Dismutase (SOD) Activity
Serum levels of superoxide dismutase (SOD) activity will be measured using a commercial ELISA kit.
Time frame: At week 1, week 3, week 4 and week 6.
Catalase (CAT) Activity
Serum catalase (CAT) activity will be measured using a commercial ELISA kit.
Time frame: At week 1, week 3, week 4 and week 6.
Glutathione Peroxidase (GPx) Activity
Serum levels of glutathione peroxidase (GPx) activity will be measured using a commercial ELISA kit.
Time frame: At week 1, week 3, week 4 and week 6.
Serum High-Sensitivity C-Reactive Protein (hs-CRP) Levels
Serum levels of high-sensitivity C-reactive protein (hs-CRP) will be measured using turbidimetric methods.
Time frame: At week 1, week 3, week 4 and week 6.
Plasma Monocyte Chemoattractant Protein-1 (MCP-1) Levels
Plasma levels of monocyte chemoattractant protein-1 (MCP-1) will be measured using a commercial multiplex Cytometric Bead Array kit.
Time frame: At week 1, week 3, week 4 and week 6.
Plasma Interleukin-6 (IL-6) Levels
Plasma levels of interleukin-6 (IL-6) will be measured using a commercial multiplex Cytometric Bead Array kit.
Time frame: At week 1, week 3, week 4 and week 6.
Plasma Lactate Dehydrogenase (LDH) Levels
Plasma levels of lactate dehydrogenase (LDH) will be measured using commercial ELISA kits.
Time frame: At week 1, week 3, week 4 and week 6.
Plasma Creatine Kinase (CK) Levels
Plasma levels of creatine kinase (CK) will be measured using commercial ELISA kits
Time frame: At week 1, week 3, week 4 and week 6.
Serum Cortisol Levels
Serum cortisol levels will be determined using electrochemiluminescence methods.
Time frame: At week 1, week 3, week 4 and week 6.
Urinary Creatinine Levels
Urinary creatinine levels will be measured using a commercial ELISA kit
Time frame: At week 1, week 3, week 4 and week 6.
Maximal Oxygen Uptake (VO₂ max)
VO₂ max. be assessed through a graded exercise test. This data will be used to calibrate subsequent treadmill sessions at 80% of each participant's VO₂ max.
Time frame: At week 1.
Heart Rate, Treadmill Speed and Incline
Heart rate, treadmill speed, and incline at the intensity of 80% of each participant's VO₂ max. will be recorded in the case report form.
Time frame: At week 1.
Physical Activity Level (Questionnaire-Based)
Physical activity level will be assessed using the "Quick Physical Activity Classifier" questionnaire, adapted from the PEFS Guide of the Catalan Government.
Time frame: At week 0, week 1, week 3, week 4 and week 6.
Whole Blood Transcriptomic Profile (RNA-seq)
Gene expression will be analyzed in whole blood samples preserved in PAXgene Blood RNA tubes.
Time frame: At week 1, week 3, week 4 and week 6.
Concomitant medication
The use of any concomitant medication will be recorded through participant-reported entries in the case report form.
Time frame: At week 0, week 1, week 3, week 4 and week 6.
Heart Rate
Heart rate will be measured using the Omron HEM-907 monitor.
Time frame: At week 0, week 1, week 3, week 4 and week 6.
Systolic Blood Pressure
Systolic Blood Pressure will be measured using the Omron HEM-907 monitor.
Time frame: At week 0, week 1, week 3, week 4 and week 6.
Diastolic Blood Pressure
Diastolic Blood Pressure will be measured using the Omron HEM-907 monitor.
Time frame: At week 0, week 1, week 3, week 4 and week6.
Use of Dietary Supplements
Dietary supplements consumed during the study will be recorded in the case report form.
Time frame: At week 0, week 1, week 3, week 4 and week 6.
Intervention Compliance (Supplement Intake Adherence)
Compliance with the intervention will be assessed indirectly by calculating the ratio between the number of supplement sachets theoretically assigned and the number actually consumed.
Time frame: At week 3 and week 6.
Adverse events
Possible adverse events derived from taking study's products will be recorded in the case report form
Time frame: At week 3 and week 6.
Plan to share: No
Started Aug 2025 (actual). Primary completion is estimated for Nov 2025, 3 months after the start.
Of 5,176 non-industry interventional studies with no phase under Motor Activity, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 36. This study's planned 3 months is below that.
Counting every sponsor, half of 5,236 studies reached it within 17 months; a quarter within 7 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundació Eurecat